Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections.
- Author:
Junyang KUAI
1
;
Xiaojuan WANG
1
;
Hui WANG
1
Author Information
- Publication Type:Review
- Keywords: in vitro antibacterial activity; cefiderocol; pharmacodynamics; pharmacokinetics; siderophore cephalosporin
- MeSH: Cephalosporins/therapeutic use*; Gram-Negative Bacteria; Microbial Sensitivity Tests; Siderophores/pharmacology*
- From: Chinese Journal of Biotechnology 2022;38(3):990-1003
- CountryChina
- Language:Chinese
- Abstract: Antimicrobial resistance is one of the critical public health issues in the world. There is an urgent need to develop effective broad-spectrum antibiotics to treat the infection of multi-drug resistant Gram-negative bacilli. Cefiderocol, developed by the Shionogi Inc. in Japan, is a new type of iron carrier cephalosporin antibiotics, which overcomes the drug resistance of Gram-negative bacilli due to the down-regulation of outer membrane pore protein and the up-regulation of efflux pump, and has good stability to serine- and metallo-carbapenemases. This drug has a broad spectrum and strong antibacterial activity against carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia. Cefiderocol can be used to treat complex urinary tract infections (including pyelonephritis), hospital-acquired pneumonia, and ventilator-associated pneumonia. By summarizing the chemical structure, antibacterial mechanism, in vitro antibacterial activity, pharmacokinetics, pharmacodynamics, and clinical treatment of cefiderocol, this review shows the application potential of cefiderocol as a new iron carrier cephalosporin in the treatment of multi-drug resistant Gram-negative bacilli infections.
